Additionally, trials incorporating newer antihypertensive agents, including SGLT2 inhibitors and mineralocorticoid receptor antagonists, could provide insights into synergistic or comparative effectiveness in various CKD stages. The gene discussed is SLC5A2; the disease is chronic kidney disease.